Patents by Inventor Delphine Behr-Roussel

Delphine Behr-Roussel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATING AND PHARMACEUTICAL COMPOSITIONS
    Publication number: 20240082284
    Abstract: The invention relates to methods for improving glycemic control and for treating erectile dysfunction in a patient diagnosed with prediabetes, type 1 diabetes mellitus, type 2 diabetes mellitus or metabolic syndrome wherein a sodium glucose co-transporter 2 (SGLT2) inhibitor is administered to the patient. Furthermore the invention relates to a method for improving a treatment of erectile dysfunction in a male patient diagnosed with prediabetes, type 1 diabetes mellitus or type 2 diabetes mellitus characterized in that in addition to the treatment of erectile dysfunction a SGLT2 inhibitor is administered to the patient. The invention also relates a pharmaceutical composition comprising a SGLT2 inhibitor and a compounds selected from the group consisting of phosphodiesterase 5 (PDE5) inhibitors or alprostadil.
    Type: Application
    Filed: November 10, 2023
    Publication date: March 14, 2024
    Inventors: Eric Williams MAYOUX, Delphine BEHR-ROUSSEL, Francois GIULIANO
  • Methods for treating and Pharmaceutical compositions
    Publication number: 20220193101
    Abstract: The invention relates to methods for improving glycemic control and for treating erectile dysfunction in a patient diagnosed with prediabetes, type 1 diabetes mellitus, type 2 diabetes mellitus or metabolic syndrome wherein a SGLT2 inhibitor is administered to the patient. Furthermore the invention relates to a method for improving a treatment of erectile dysfunction in a male patient diagnosed with prediabetes, type 1 diabetes mellitus or type 2 diabetes mellitus characterized in that in addition to the treatment of erectile dysfunction a SGLT2 inhibitor is administered to the patient. The invention also relates a pharmaceutical composition comprising a SGLT2 inhibitor and a compounds selected from the group consisting of PDE5 inhibitors or alprostadil.
    Type: Application
    Filed: October 5, 2021
    Publication date: June 23, 2022
    Inventors: Eric Williams MAYOUX, Delphine BEHR-ROUSSEL, Francois GIULIANO
  • METHODS AND PHARMACEUTICAL COMPOSITIONS COMPRISING A SGLT2 INHIBITOR FOR TREATING OR IMPROVING ERECTILE DYSFUNCTION
    Publication number: 20190298749
    Abstract: The invention relates to methods for improving glycemic control and for treating erectile dysfunction in a patient diagnosed with prediabetes, type 1 diabetes mellitus, type 2 diabetes mellitus or metabolic syndrome wherein a SGLT2 inhibitor is administered to the patient. Furthermore the invention relates to a method for improving a treatment of erectile dysfunction in a male patient diagnosed with prediabetes, type 1 diabetes mellitus or type 2 diabetes mellitus characterized in that in addition to the treatment of erectile dysfunction a SGLT2 inhibitor is administered to the patient. The invention also relates a pharmaceutical composition comprising a SGLT2 inhibitor and a compounds selected from the group consisting of PDE5 inhibitors or alprostadil.
    Type: Application
    Filed: June 19, 2019
    Publication date: October 3, 2019
    Inventors: Eric Williams MAYOUX, Delphine BEHR-ROUSSEL, Francois GIULIANO
  • METHODS AND PHARMACEUTICAL COMPOSITIONS COMPRISING A SGLT2 INHIBITOR FOR TREATING OR IMPROVING ERECTILE DYSFUNCTION
    Publication number: 20180104268
    Abstract: The invention relates to methods for improving glycemic control and for treating erectile dysfunction in a patient diagnosed with prediabetes, type 1 diabetes mellitus, type 2 diabetes mellitus or metabolic syndrome wherein a SGLT2 inhibitor is administered to the patient. Furthermore the invention relates to a method for improving a treatment of erectile dysfunction in a male patient diagnosed with prediabetes, type 1 diabetes mellitus or type 2 diabetes mellitus characterized in that in addition to the treatment of erectile dysfunction a SGLT2 inhibitor is administered to the patient. The invention also relates a pharmaceutical composition comprising a SGLT2 inhibitor and a compounds selected from the group consisting of PDE5 inhibitors or alprostadil.
    Type: Application
    Filed: April 28, 2016
    Publication date: April 19, 2018
    Inventors: Eric Williams MAYOUX, Delphine BEHR-ROUSSEL, Francois GIULIANO
  • Use of a Combination of Udenafil and Alfuzosin or Oxybutynin for the Treatment of Overactive Bladder
    Publication number: 20110021542
    Abstract: The invention relates to a specific combination of two active agents: udenafil and one of alfuzosin and oxybutynin and its use for the treatment of overactive bladder.
    Type: Application
    Filed: April 2, 2009
    Publication date: January 27, 2011
    Applicant: PELVIPHARM
    Inventors: Francois Giuliano, Delphine Behr-Roussel